Mirum Pharmaceuticals’ (MIRM) Outperform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reissued their outperform rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report published on Wednesday morning,Benzinga reports. The firm currently has a $155.00 price objective on the stock.

Other equities research analysts have also issued research reports about the stock. UBS Group set a $137.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, August 27th. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. TD Cowen lifted their target price on shares of Mirum Pharmaceuticals from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 6th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $189.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $154.94.

Mirum Pharmaceuticals Trading Up 0.2%

Mirum Pharmaceuticals stock traded up $0.18 during trading on Wednesday, reaching $93.72. 722,713 shares of the company were exchanged, compared to its average volume of 710,635. Mirum Pharmaceuticals has a 52-week low of $63.23 and a 52-week high of $130.00. The company has a market capitalization of $6.09 billion, a P/E ratio of -6.06 and a beta of 0.75. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The stock’s 50 day simple moving average is $89.29 and its two-hundred day simple moving average is $98.46.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company had revenue of $185.72 million during the quarter, compared to analysts’ expectations of $178.07 million. During the same quarter in the previous year, the company earned $0.05 earnings per share. The firm’s quarterly revenue was up 39.6% compared to the same quarter last year. On average, equities research analysts expect that Mirum Pharmaceuticals will post -1.47 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Jolanda Howe sold 40,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the transaction, the senior vice president directly owned 1,274 shares in the company, valued at approximately $127,400. This represents a 96.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the transaction, the chief financial officer owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. This represents a 14.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 116,659 shares of company stock valued at $11,404,100 in the last quarter. Insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. ABS Investment Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter valued at about $245,847,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter valued at approximately $27,000. Quantbot Technologies LP acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $44,000. State of Wyoming acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $52,000. Finally, Summit Securities Group LLC acquired a new position in shares of Mirum Pharmaceuticals in the 1st quarter worth approximately $42,000.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $202 price target, while still projecting a path to higher earnings over the longer term; its FY2030 EPS estimate rose to $10.76 from $10.03. HC Wainwright estimates
• Positive Sentiment: Mirum’s latest quarter showed revenue up 39.6% year over year to $185.72 million, ahead of analyst expectations. The stock also moved above its 50-day moving average after the earnings release, a potentially supportive technical signal. Stock crosses 50-day moving average
• Neutral Sentiment: Leerink Partners lowered its price target to $140 from $154 but kept an “Outperform” rating. That reflects reduced upside expectations while retaining a positive view of the shares. Leerink Partners rating
• Negative Sentiment: HC Wainwright substantially cut EPS estimates for 2026 and 2027, shifting its FY2027 forecast from a $1.16 profit to a $1.28 loss. It also reduced its FY2028 estimate from $5.38 to $2.64 and FY2029 from $7.21 to $6.85, indicating weaker expected earnings in the coming years despite the maintained Buy rating. HC Wainwright revised EPS estimates
• Negative Sentiment: Quarterly EPS was a loss of $0.87, wider than the expected $0.49 loss. The earnings shortfall tempers the revenue beat and may weigh on investor sentiment. Earnings and stock outlook
• Negative Sentiment: CEO Christopher Peetz sold 20,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which may soften its significance but can still draw investor attention. CEO share sale

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.